- Home
- CBIO vs RMM Comparison
CBIO vs RMM Comparison
Compare CBIO & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- RMM
- Stock Information
- Founded
- CBIO 2003
- RMM 2019
- Country
- CBIO United States
- RMM United States
- Employees
- CBIO N/A
- RMM N/A
- Industry
- CBIO
- RMM Trusts Except Educational Religious and Charitable
- Sector
- CBIO
- RMM Finance
- Exchange
- CBIO Nasdaq
- RMM Nasdaq
- Market Cap
- CBIO 308.0M
- RMM 272.0M
- IPO Year
- CBIO N/A
- RMM N/A
- Fundamental
- Price
- CBIO $12.60
- RMM $13.75
- Analyst Decision
- CBIO Strong Buy
- RMM
- Analyst Count
- CBIO 3
- RMM 0
- Target Price
- CBIO $25.67
- RMM N/A
- AVG Volume (30 Days)
- CBIO 138.8K
- RMM 66.5K
- Earning Date
- CBIO 08-23-2025
- RMM 01-01-0001
- Dividend Yield
- CBIO N/A
- RMM 7.33%
- EPS Growth
- CBIO N/A
- RMM N/A
- EPS
- CBIO N/A
- RMM 0.96
- Revenue
- CBIO N/A
- RMM N/A
- Revenue This Year
- CBIO N/A
- RMM N/A
- Revenue Next Year
- CBIO N/A
- RMM N/A
- P/E Ratio
- CBIO N/A
- RMM $15.55
- Revenue Growth
- CBIO N/A
- RMM N/A
- 52 Week Low
- CBIO $11.06
- RMM $12.32
- 52 Week High
- CBIO $21.40
- RMM $16.10
- Technical
- Relative Strength Index (RSI)
- CBIO N/A
- RMM 51.73
- Support Level
- CBIO N/A
- RMM $13.72
- Resistance Level
- CBIO N/A
- RMM $13.86
- Average True Range (ATR)
- CBIO 0.00
- RMM 0.13
- MACD
- CBIO 0.00
- RMM -0.02
- Stochastic Oscillator
- CBIO 0.00
- RMM 13.49
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.